Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. Its drug candidates include avapritinib, BLU 554, BLU-782 and BLU-667.
IPO Date: May 1, 2015
Sector: Healthcare
Industry: Biotech
Market Cap: $8.28B
Activated in VL: True
Average Daily Range
Avg Daily Range: $1.47 | 2.36%
Avg Daily Range (30 D): $1.16 | 1.15%
Avg Daily Range (90 D): $1.65 | 1.80%
Institutional Daily Volume
Avg Daily Volume: .48M
Avg Daily Volume (30 D): 4.18M
Avg Daily Volume (90 D): 2.02M
Trade Size
Avg Trade Size (Sh.): 66
Avg Trade Size (Sh.) (30 D): 133
Avg Trade Size (Sh.) (90 D): 92
Institutional Trades
Total Inst.Trades: 6,524
Avg Inst. Trade: $3.45M
Avg Inst. Trade (30 D): $6.02M
Avg Inst. Trade (90 D): $6.1M
Avg Inst. Trade Volume: .05M
Avg Inst. Trades (Per Day): 3
Market Closing Trades
Avg Closing Trade: $5.59M
Avg Closing Trade (30 D): $17.96M
Avg Closing Trade (90 D): $14.6M
Avg Closing Volume: 73.67K
   
News
Jun 15, 2025 @ 7:51 PM
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Invest...
Source: N/A
Jun 15, 2025 @ 5:53 PM
HAPPY FATHER’S DAY! and $HAREHOLDER ALERT: ...
Source: Juan Monteverde
Jun 15, 2025 @ 5:37 PM
HAPPY FATHER’S DAY! and $HAREHOLDER ALERT: ...
Source: Juan Monteverde
Jun 15, 2025 @ 5:31 PM
HAPPY FATHER’S DAY! and $HAREHOLDER ALERT: ...
Source: Juan Monteverde
Jun 15, 2025 @ 5:27 PM
HAPPY FATHER’S DAY! and $HAREHOLDER ALERT: ...
Source: Juan Monteverde
Financials
  TTM Q1 2025 Q4 2024
Basic EPS $-2.48 $.01 $-.8
Diluted EPS $-2.48 $.01 $-.8
Revenue $ 562.12M $ 149.41M $ 146.37M
Gross Profit $ 542.35M $ 146.61M $ 138.92M
Net Income / Loss $ -155.73M $ .5M $ -49.96M
Operating Income / Loss $ -174.31M $ -41.09M $ -41.2M
Cost of Revenue $ 19.77M $ 2.8M $ 7.45M
Net Cash Flow $ 10.24M $ 19.79M $ 14.1M
PE Ratio